Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
OTCMKTS:BAYRY

Bayer Aktiengesellschaft Q1 2025 Earnings Results & Report

Bayer Aktiengesellschaft logo
$12.24 +0.17 (+1.41%)
As of 10/9/2026 03:59 PM Eastern

Bayer Aktiengesellschaft beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 13, 2025. The company reported EPS of $0.65 versus the $0.63 consensus estimate, while revenue of $15.27 billion topped the $13.39 billion estimate by $1.87 billion.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.65
Consensus EPS
$0.63
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$15.27 billion
Expected Revenue
$13.39 billion
Beat/Miss
Beat by +$1.87 billion
YoY Revenue Growth
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Q1 2025 Earnings FAQ

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) reported earnings of $0.65 per share for Q1 2025, beating the consensus estimate of $0.63. The report was announced on Tuesday, May 13, 2025.

Bayer Aktiengesellschaft reported revenue of $15.27 billion for Q1 2025, against a consensus estimate of $13.39 billion.

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bayer Aktiengesellschaft on the company's earnings history page.

Bayer Aktiengesellschaft Earnings Headlines

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
October 8 at 4:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261007322202/en/Bayer-to-Present-New-Cardiac-Amyloidosis-and-Heart-Failure-Data-at-the-Heart-Failure-Society-of-America-HFSA-Annual-Scientific-Meeting/
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
October 8 at 2:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261007583229/en/u.s.-fda-accepts-bayer%e2%80%99s-supplemental-new-drug-application-for-kerendia%c2%ae-finerenone-to-treat-adults-with-chronic-kidney-disease-ckd-without-diabetes/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 11 at 1:00 AM  |  Chaikin Analytics (Ad)
Bayer’s Real‑World Prostate Cancer Study Signals Key Trends for Treatment Adoption in Canada
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bayers-realworld-prostate-cancer-study-signals-key-trends-for-treatment-adoption-in-canada?utm_source=marketbeat.com&utm_medium=referral
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
October 2, 2026  |  wsj.comhttps://www.wsj.com/health/pharma/bayer-to-invest-2-2-billion-in-u-s-pharma-manufacturing-expansion-ec038b86
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261002202241/en/bayer-to-invest-2.2-billion-u.s.-dollars-in-a-new-manufacturing-site-in-the-united-states/
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin. The Crop Science business supplies seeds, crop protection products and digital agricultural solutions for farmers and other agricultural customers.

Founded in 1863, Bayer is headquartered in Leverkusen, Germany, and serves customers in markets around the world. The company expanded its agricultural operations through the acquisition of Monsanto in 2018, adding seed and crop protection businesses to its portfolio. Bayer is led by Chief Executive Officer Bill Anderson, who assumed the role in June 2023.

View Bayer Aktiengesellschaft Profile
Earnings Tools